Ifeanyichukwu Ifechidere: DOAC Monitoring – What To Order, When, And Why
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“Not every patient on a DOAC needs monitoring.
But when they do, ordering the wrong assay can lead to the wrong clinical decision.
This is where many clinicians-and even laboratories-get caught out.
The question isn’t just ‘Should I measure the DOAC?’
It’s ‘Which assay answers my clinical question?’
Here’s a simple way to think about it:
- Anti-Xa assay
- Best for rivaroxaban, apixaban, and edoxaban
- Use a drug-specific calibrated Anti-Xa assay
- Helpful in major bleeding, urgent surgery, suspected overdose, renal impairment, or unexpected thrombosis.
Dilute Thrombin Time (dTT)
- Best for dabigatran
- Provides a quantitative estimate of dabigatran concentration.
- More reliable than routine clotting tests.
DOAC Screen
- Useful as a rapid screening tool to determine whether a clinically significant DOAC is present.
- Helpful in emergency settings when the anticoagulant history is uncertain.
- It is not a substitute for drug-specific quantification.
And here’s the part that’s often overlooked…
Timing matters just as much as assay selection.
A result is difficult to interpret unless you know:
- Which DOAC the patient is taking
- The dose
- The time of the last dose
- Renal function
- Whether you’re measuring a peak or trough level
Without that context, even the ‘right’ test can produce a misleading interpretation.
The takeaway:
The goal of DOAC testing isn’t simply to detect the drug.
It’s to answer a specific clinical question with the right assay at the right time.
What is the biggest challenge your laboratory or clinical team faces when interpreting DOAC assays?”

Find more posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Nov 15, 2026, 09:41Girishkumar Modi: Navigating the 2026 Jehovah’s Witness Transfusion Policy Shift in Clinical Practice
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning